Evidence map›Paper›PMID 40584900›Full record

ReviewBioImpacts : BI2025

The promise of gene therapy in common types of dementia.

Mojtaba Ghobadi, Mohammad Foad Heidari, Arezoo Farhadi, Ali Shakerimoghaddam, Mahdi Ghorbani, Zahra Hami, Naeim Ehtesham, Javad Behroozi

Abstract readReview
In one paragraph

Review in BioImpacts : BI, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mojtaba GhobadiCancer Epidemiology Research Center, Aja University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-8629-4510
Mohammad Foad HeidariDepartment of Medical Laboratory Sciences, School of Allied Health Medicine, AJA Univers.
Arezoo FarhadiDepartment of Genetics and Molecular Medicine, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Ali ShakerimoghaddamInfectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran.
Mahdi GhorbaniCancer Epidemiology Research Center, Aja University of Medical Sciences, Tehran, Iran.
Zahra HamiToxicology Research Center, AJA University of Medical Sciences, Tehran, Iran.
Naeim EhteshamDepartment of Meical Genetics, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Javad BehrooziCancer Epidemiology Research Center, Aja University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0001-6429-0295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dementia is an umbrella term describing different types of diseases that lead to cognitive impairment and memory dysfunction, predominantly affecting older adults. The most common forms include Alzheimer's disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Despite extensive research, there is no definitive cure for dementia, primarily due to its complex and multifactorial nature, particularly the role of genetic abnormalities. Gene therapy, a novel therapeutic approach, aims to correct defective genes or introduce functional gene products by delivering specific DNA sequences to patients, and is often considered for individuals unresponsive to conventional treatments, such as those with dementia. Over the past decade, significant research has explored the potential of gene therapy in dementia, offering new hope for more effective treatments. However, several challenges remain in its practical application. One key challenge is developing safe and efficient gene delivery methods, as the brain's intricate structure and protective barriers present significant obstacles. Furthermore, ensuring the long-term expression and stability of therapeutic genes is crucial for sustained benefit. Future studies should focus on identifying genes implicated in different types of dementia, optimizing gene delivery systems, improving gene-targeting specificity, and conducting comprehensive clinical trials to assess the safety and efficacy of these therapies. Addressing these challenges could pave the way for novel treatment strategies, ultimately improving the quality of life for individuals with dementia.

Indexed as

Alzheimer's diseaseCRISPRFrontotemporal dementiasGene therapyParkinson's diseaseVascular dementia

Identifiers

PMID40584900
PMCPMC12204781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.